Sorry, you need to enable JavaScript to visit this website.

Pfizer Announces DUAVEE® (conjugated estrogens/bazedoxifene), an Estrogen-Based Menopause Hormone Therapy, Now Back in Stock with Improved Packaging

NEW YORK, June 5, 2023 – Pfizer Inc. (NYSE: PFE) today announced that DUAVEE® (conjugated estrogens/bazedoxifene), an estrogen-based menopause hormone therapy, is now back in stock in the United States, with improved packaging, following a voluntary recall. The recall was due to an issue with the packaging and was not based on any efficacy or safety concerns with the product itself.

Subscribe to Updates